# US 2022/0031795 A1 · Compound for treating oxidative stress in mammals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031795 A1
- Document ID: US20220031795A1
- Status: Published application
- Kind: A1
- Application number: 17/501,309
- Filed: 2021-10-14
- Published: 2022-02-03
- Earliest claimed: 2019-12-23
- Assignees: Hemopet
- Applicants: Hemopet
- Inventors: Winifred Jean Dodds
- Web page: https://patentgrep.com/patent/US20220031795A1

## CPC

- A61K 36/9068: Zingiber, e.g. garden ginger
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 36/484: Glycyrrhiza (licorice)
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 36/88: Liliopsida (monocotyledons)
- A61K 36/8962: Allium, e.g. garden onion, leek, garlic or chives
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/88: involving prostaglandins {or their receptors}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2800/7009: Oxidative stress
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E or selenium. Diagnosing an oxidative stress (OS) in a mammal comprises collecting a sample; screening the sample to detect the presence of an OS biomarker, selectively isoprostane and other antioxidants such as HODE microRNAs. TAC: GSH, MDA, and TNF-alpha. The sample can be saliva.

## Claims

### Claim 1

A method of using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog, the composition being a combination at least vitamin D and selenium ingredients alpha-lipoic acid, co-enzyme Q-10, green tea, and turmeric, the ingredients being mixed together in powdered form and mixed into the food and being for ingestion by the dog together with food, including the screening a saliva sample of a dog to detect a level of at least an OS isoprostane biomarker; detecting the presence of the OS isoprostane biomarker based on a quantitative level of the OS isoprostane biomarker, diagnosing the degree of OS in the dog based on an increased quantitative level of the OS isoprostane biomarker, and treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the isoprostane biomarker in the dog so treated by the composition combination is reduced.

### Claim 2 (depends on 1)

The method for treating oxidative stress (OS) as claimed in claim 1 including treating an elevated HODE OS biomarker in the dog.

### Claim 3 (depends on 2)

The method for treating oxidative stress (OS) as claimed in claim 2 including in the combination at least two supplements selected from the group consisting of ginger, licorice and garlic.

### Claim 4 (depends on 2)

The method for treating oxidative stress (OS) as claimed in claim 2 including in the combination ginger, licorice and garlic.

### Claim 5 (depends on 1)

The method of claim 1 wherein the isoprostane biomarker level is reduced by at least 40%.

### Claim 6 (depends on 1)

The method of claim 1 wherein the isoprostane biomarker level is reduced by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml as measured in saliva from the dog.

### Claim 7

A method of using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog, the composition being a combination at least Alpha-Lipoic acid in an amount between 50 mg and 100 mg; Co-Enzyme Q-10 in an amount between 5 mg and 20 mg; Green tea in an amount between 50 mg and 200 mg; Selenium in an amount between 5 mcg and 20 mcg; Turmeric (curcumin) in an amount between 20 mg and 300 mg; Vitamin D in an amount between 25 mcg and 150 mcg; the ingredients being mixed together in powdered form and mixed into the food and being for ingestion by the dog together with food, including the screening a saliva sample of a dog to detect a level of at least an OS isoprostane biomarker; detecting the presence of the OS isoprostane biomarker based on a quantitative level of the OS isoprostane biomarker, diagnosing the degree of OS in the dog based on an increased quantitative level of the OS isoprostane biomarker, and treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the isoprostane biomarker in the dog so treated by the composition combination is reduced.

### Claim 8 (depends on 7)

The method for treating oxidative stress (OS) as claimed in claim 7 including treating an elevated HODE OS biomarker in the dog.

### Claim 9 (depends on 7)

The method for treating oxidative stress (OS) as claimed in claim 7 including in the combination at least two supplements selected from the group consisting of ginger, licorice and garlic.

### Claim 10 (depends on 7)

The method for treating oxidative stress (OS) as claimed in claim 7 including in the combination ginger, licorice and garlic.

### Claim 11 (depends on 7)

The method of claim 7 wherein the isoprostane biomarker level is reduced by at least 40%.

### Claim 12 (depends on 7)

The method of claim 7 wherein the isoprostane biomarker level is reduced by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml as measured in saliva from the dog.

### Claim 13

A method of using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog, the composition being a combination at least Alpha-Lipoic acid in an amount of about 20 mg; Co-Enzyme Q-10 in an amount of about 10 mg; Green tea in an amount of about 100 mg; Selenium in an amount of about 10 mcg; Turmeric (curcumin) in an amount of about 100 mg; Vitamin D in an amount of about 75 mcg; the ingredients being mixed together in powdered form and mixed into the food and being for ingestion by the dog together with food, including the screening a saliva sample of a dog to detect a level of at least an OS isoprostane biomarker; detecting the presence of the OS isoprostane biomarker based on a quantitative level of the OS isoprostane biomarker, diagnosing the degree of OS in the dog based on an increased quantitative level of the OS isoprostane biomarker, and treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the isoprostane biomarker in the dog so treated by the composition combination is reduced.

### Claim 14 (depends on 13)

The method for treating oxidative stress (OS) as claimed in claim 13 including treating an elevated HODE OS biomarker in the dog.

### Claim 15 (depends on 13)

The method for treating oxidative stress (OS) as claimed in claim 13 including in the combination at least two supplements selected from the group consisting of ginger, licorice and garlic.

### Claim 16 (depends on 13)

The method for treating oxidative stress (OS) as claimed in claim 13 including in the combination ginger, licorice and garlic.

### Claim 17 (depends on 13)

The method of claim 13 wherein the isoprostane biomarker level is reduced by at least 40%.

### Claim 18 (depends on 13)

The method of claim 13 wherein the isoprostane biomarker level is reduced by at least 40% after five to six months from an elevated level to a level below 1.75 ng/ml as measured in saliva from the dog.
